Skip to content

Reported May 13, 2025 · After market close

Revenue estimate$15.1M
EPS estimate$0.09

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$26.9M
EPS estimate$0.13

Financials

Q1 2025

Income statement

See full
Revenue$17.3M+117%
Gross profit$9.9M+96.9%
Operating income-$470.0K+41.3%
Net income-$1.6M-93.8%
EPS (diluted)-$0.06-100%

Balance sheet

See full
Cash & equivalents$17.4M+4.6%
Total debt$30.2M+490%
Total equity$24.5M+57.8%
Total assets$84.0M+173%

Cash flow

See full
Operating cash flow$2.1M+185%
CapEx--100%
Free cash flow$2.1M+184%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$348.09M+261%
Enterprise value$360.83M+326%
P/S7.2×+4.4×

Profitability

See full
Gross margin58.5%-7.8pp
Net margin-9.5%-12.1pp

Returns & leverage

See full
Return on equity-23%-29.8pp
Debt / equity1.2×+0.9×
Current ratio+0.4×

Versus estimates

Ask the moment Eton Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Eton Pharmaceuticals, Inc. report Q1 2025 earnings?
Eton Pharmaceuticals, Inc. (ETON) reported Q1 2025 earnings on May 13, 2025 after market close.
What were Eton Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
Eton Pharmaceuticals, Inc. reported revenue of $17.3M and diluted EPS of $0.07 for Q1 2025.
Did Eton Pharmaceuticals, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $15.1M by $2.2M. EPS missed the consensus estimate of $0.09 by $0.02.
How did Eton Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 116.9% from $8.0M a year earlier.
Where can I find Eton Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0001437749-25-016475) directly on SEC EDGAR. The filing index links above go to sec.gov.